Summary
Stryker Corporation's 2014 Form 10-K reveals a company with robust revenue growth, achieving $9.675 billion in net sales, a 7.3% increase year-over-year. This growth was driven by strong performance across its three key segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with particular strength noted in instruments, trauma and extremities, and neurotechnology products. The company continued its strategic focus on acquisitions, investing $916 million in 2014 to expand its product offerings and market reach. However, net earnings experienced a significant decline of 48.8% to $515 million, largely impacted by substantial recall charges related to hip stems, totaling $761 million. Despite this, Stryker maintained a strong financial position with $5 billion in cash, cash equivalents, and marketable securities, indicating good liquidity. The company also demonstrated its commitment to returning value to shareholders through dividend payments and share repurchases, while continuing to invest in research and development to fuel future innovation.
Financial Highlights
53 data points| Revenue | $9.68B |
| Cost of Revenue | $3.32B |
| Gross Profit | $6.36B |
| R&D Expenses | $614.00M |
| SG&A Expenses | $3.55B |
| Operating Expenses | $5.11B |
| Operating Income | $1.25B |
| Interest Expense | $113.00M |
| Net Income | $515.00M |
| EPS (Basic) | $1.36 |
| EPS (Diluted) | $1.34 |
| Shares Outstanding (Basic) | 378.50M |
| Shares Outstanding (Diluted) | 382.80M |
Key Highlights
- 1Stryker reported 2014 net sales of $9.675 billion, an increase of 7.3% over 2013, indicating strong top-line growth.
- 2The company made significant strategic acquisitions in 2014, including SBi ($358M), Berchtold ($184M), and PST ($120M), to enhance its product portfolio.
- 3Net earnings saw a substantial decrease of 48.8% to $515 million, primarily due to significant recall charges related to the Rejuvenate and ABG II hip stems, amounting to $761 million.
- 4The company's cash position remained strong, with $5 billion in cash, cash equivalents, and marketable securities at year-end 2014, providing ample liquidity.
- 5Stryker continued to return capital to shareholders through dividends ($462M paid in 2014) and share repurchases ($100M in 2014).
- 6Research, development, and engineering expenses increased to 6.3% of sales in 2014, reflecting continued investment in innovation.
- 7The company managed its debt effectively, increasing total debt to $3.973 billion in 2014, primarily to fund acquisitions and other strategic initiatives.